{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:08:16Z","timestamp":1779235696596,"version":"3.51.4"},"reference-count":57,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1097\/bor.0b013e328356d9f6","type":"journal-article","created":{"date-parts":[[2012,7,18]],"date-time":"2012-07-18T10:39:33Z","timestamp":1342607973000},"page":"649-655","source":"Crossref","is-referenced-by-count":27,"title":["Lipids and eicosanoids in fibrosis"],"prefix":"10.1097","volume":"24","author":[{"given":"Flavia V.","family":"Castelino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-11-20210128","doi-asserted-by":"crossref","first-page":"136","DOI":"10.7326\/0003-4819-134-2-200101160-00015","article-title":"Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy.","volume":"134","author":"Selman","year":"2001","journal-title":"Ann Intern Med"},{"key":"R2-11-20210128","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.bbalip.2008.06.005","article-title":"Two pathways for lysophosphatidic acid production.","volume":"1781","author":"Aoki","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"R3-11-20210128","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/bies.20081","article-title":"The ins and outs of lysophosphatidic acid signaling.","volume":"26","author":"Moolenaar","year":"2004","journal-title":"Bioessays"},{"key":"R4-11-20210128","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.molmed.2005.12.001","article-title":"Emerging medicinal roles for lysophospholipid signaling.","volume":"12","author":"Gardell","year":"2006","journal-title":"Trends Mol Med"},{"key":"R5-11-20210128","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nm1685","article-title":"The lysophosphatidic acid receptor LPA(1) links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak.","volume":"14","author":"Tager","year":"2008","journal-title":"Nat Med"},{"key":"R6-11-20210128","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/art.30262","article-title":"Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma.","volume":"63","author":"Castelino","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R7-11-20210128","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.semcdb.2004.05.001","article-title":"Mechanisms of lysophosphatidic acid production.","volume":"15","author":"Aoki","year":"2004","journal-title":"Semin Cell Dev Biol"},{"key":"R8-11-20210128","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.0022-202X.2005.23855.x","article-title":"Production of lysophosphatidic acid in blister fluid: involvement of a lysophospholipase D activity.","volume":"125","author":"Mazereeuw-Hautier","year":"2005","journal-title":"J Invest Dermatol"},{"key":"R9-11-20210128","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1165\/rcmb.2010-0155OC","article-title":"The lysophosphatidic acid receptor LPA1 promotes epithelial cell apoptosis after lung injury.","volume":"46","author":"Funke","year":"2012","journal-title":"Am J Respir Cell Mol Biol"},{"key":"R10-11-20210128","doi-asserted-by":"crossref","first-page":"168","DOI":"10.7150\/ijms.6.168","article-title":"Elevated serum levels of arachidonoyl-lysophosphatidic acid and sphingosine 1-phosphate in systemic sclerosis.","volume":"6","author":"Tokumura","year":"2009","journal-title":"Int J Med Sci"},{"key":"R11-11-20210128","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1681\/ASN.2007020196","article-title":"LPA1 receptor activation promotes renal interstitial fibrosis.","volume":"18","author":"Pradere","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R12-11-20210128","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1006\/bbrc.1998.8983","article-title":"Effects of lysophosphatidic acid on proliferation of stellate cells and hepatocytes in culture.","volume":"248","author":"Ikeda","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"key":"R13-11-20210128","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1164\/rccm.200804-595SO","article-title":"Sphingolipids in the lungs.","volume":"178","author":"Uhlig","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"R14-11-20210128","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.tcb.2011.09.003","article-title":"Sphingosine-1-phosphate signaling and its role in disease.","volume":"22","author":"Maceyka","year":"2012","journal-title":"Trends Cell Biol"},{"key":"R15-11-20210128","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.semcdb.2004.05.007","article-title":"Lysophosphatidic acid and sphingosine 1-phosphate biology: the role of lipid phosphate phosphatases.","volume":"15","author":"Pyne","year":"2004","journal-title":"Semin Cell Dev Biol"},{"key":"R16-11-20210128","first-page":"25","article-title":"Biological effects of lysophospholipids.","volume":"160","author":"Rivera","year":"2008","journal-title":"Rev Physiol Biochem Pharmacol"},{"key":"R17-11-20210128","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1165\/rcmb.2009-0345OC","article-title":"Prolonged exposure to sphingosine 1-phosphate receptor-1 agonists exacerbates vascular leak, fibrosis, and mortality after lung injury.","volume":"43","author":"Shea","year":"2010","journal-title":"Am J Respir Cell Mol Biol"},{"key":"R19-11-20210128","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1136\/thoraxjnl-2011-200026","article-title":"Sphingosine-1-phosphate is increased in patients with idiopathic pulmonary fibrosis and mediates epithelial to mesenchymal transition.","volume":"67","author":"Milara","year":"2012","journal-title":"Thorax"},{"key":"R20-11-20210128","doi-asserted-by":"crossref","first-page":"19593","DOI":"10.1074\/jbc.M802417200","article-title":"Opposite effects of dihydrosphingosine 1-phosphate and sphingosine 1-phosphate on transforming growth factor-betaSmad signaling are mediated through the PTENPPM1A-dependent pathway.","volume":"283","author":"Bu","year":"2008","journal-title":"J Biol Chem"},{"key":"R21-11-20210128","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/nrd3248","article-title":"Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis.","volume":"9","author":"Brinkmann","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"R22-11-20210128","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMra1104901","article-title":"The human plasma lipidome.","volume":"365","author":"Quehenberger","year":"2011","journal-title":"N Engl J Med"},{"key":"R23-11-20210128","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1002\/art.27463","article-title":"Dihydrosphingosine 1-phosphate has a potent antifibrotic effect in scleroderma fibroblasts via normalization of phosphatase and tensin homolog levels.","volume":"62","author":"Bu","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R24-11-20210128","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1042\/CS20050012","article-title":"Eicosanoids: mediators and therapeutic targets in fibrotic lung disease.","volume":"108","author":"Charbeneau","year":"2005","journal-title":"Clin Sci (Lond)"},{"key":"R25-11-20210128","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1165\/rcmb.2011-0025RT","article-title":"Prostaglandin E2 and the pathogenesis of pulmonary fibrosis.","volume":"45","author":"Bozyk","year":"2011","journal-title":"Am J Respir Cell Mol Biol"},{"key":"R26-11-20210128","doi-asserted-by":"crossref","first-page":"L1257","DOI":"10.1152\/ajplung.2001.281.5.L1257","article-title":"Prostaglandin E(2) inhibits fibroblast chemotaxis.","volume":"281","author":"Kohyama","year":"2001","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"R27-11-20210128","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1172\/JCI112364","article-title":"Modulation of alveolar macrophage-driven fibroblast proliferation by alternative macrophage mediators.","volume":"77","author":"Bitterman","year":"1986","journal-title":"J Clin Invest"},{"key":"R28-11-20210128","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1152\/physrev.1999.79.4.1193","article-title":"Prostanoid receptors: structures, properties, and functions.","volume":"79","author":"Narumiya","year":"1999","journal-title":"Physiol Rev"},{"key":"R29-11-20210128","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/S0002-9440(10)63423-2","article-title":"Severity of lung injury in cyclooxygenase-2-deficient mice is dependent on reduced prostaglandin E(2) production.","volume":"165","author":"Hodges","year":"2004","journal-title":"Am J Pathol"},{"key":"R30-11-20210128","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1172\/JCI117866","article-title":"Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin E2 and to express cyclooxygenase-2.","volume":"95","author":"Wilborn","year":"1995","journal-title":"J Clin Invest"},{"key":"R31-11-20210128","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1164\/rccm.200905-0674OC","article-title":"Diminished prostaglandin E2 contributes to the apoptosis paradox in idiopathic pulmonary fibrosis.","volume":"182","author":"Maher","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"R32-11-20210128","doi-asserted-by":"crossref","first-page":"5644","DOI":"10.4049\/jimmunol.174.9.5644","article-title":"Bleomycin-induced E prostanoid receptor changes alter fibroblast responses to prostaglandin E2.","volume":"174","author":"Moore","year":"2005","journal-title":"J Immunol"},{"key":"R33-11-20210128","doi-asserted-by":"crossref","first-page":"637","DOI":"10.4049\/jimmunol.180.1.637","article-title":"Prostaglandin E2 mediates IL-1beta-related fibroblast mitogenic effects in acute lung injury through differential utilization of prostanoid receptors.","volume":"180","author":"White","year":"2008","journal-title":"J Immunol"},{"key":"R34-11-20210128","doi-asserted-by":"crossref","first-page":"7220","DOI":"10.1073\/pnas.96.13.7220","article-title":"Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target.","volume":"96","author":"Jakobsson","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R35-11-20210128","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1006\/bbrc.2002.6531","article-title":"Identification and characterization of a novel type of membrane-associated prostaglandin E synthase.","volume":"291","author":"Tanikawa","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"key":"R36-11-20210128","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1124\/pr.59.3.1","article-title":"Membrane prostaglandin E synthase-1: a novel therapeutic target.","volume":"59","author":"Samuelsson","year":"2007","journal-title":"Pharmacol Rev"},{"key":"R37-11-20210128","doi-asserted-by":"crossref","first-page":"R61","DOI":"10.1186\/ar3285","article-title":"mPGES-1 null mice are resistant to bleomycin-induced skin fibrosis.","volume":"13","author":"McCann","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"R38-11-20210128","first-page":"1909","article-title":"Identification and development of mPGES-1 inhibitors: where we are at Future Med C","volume":"3","author":"Chang","year":"2011","journal-title":"hem"},{"key":"R39-11-20210128","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/nm.2066","article-title":"Prostaglandin F(2alpha) receptor signaling facilitates bleomycin-induced pulmonary fibrosis independently of transforming growth factor-beta.","volume":"15","author":"Oga","year":"2009","journal-title":"Nat Med"},{"key":"R40-11-20210128","doi-asserted-by":"crossref","first-page":"L142","DOI":"10.1152\/ajplung.00102.2006","article-title":"Revisiting prostacyclin: new directions in pulmonary fibrosis and inflammation.","volume":"291","author":"Soberman","year":"2006","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"R41-11-20210128","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1465-9921-11-34","article-title":"A prostacyclin analogue, iloprost, protects from bleomycin-induced pulmonary fibrosis in mice.","volume":"11","author":"Zhu","year":"2010","journal-title":"Respir Res"},{"key":"R42-11-20210128","doi-asserted-by":"crossref","first-page":"L645","DOI":"10.1152\/ajplung.00176.2011","article-title":"Prostaglandin E(2) protects murine lungs from bleomycin-induced pulmonary fibrosis and lung dysfunction.","volume":"301","author":"Dackor","year":"2011","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"R43-11-20210128","doi-asserted-by":"crossref","first-page":"684","DOI":"10.7326\/0003-4819-121-9-199411010-00010","article-title":"The role of leukotrienes in inflammation.","volume":"121","author":"Henderson","year":"1994","journal-title":"Ann Intern Med"},{"key":"R44-11-20210128","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.plefa.2005.05.002","article-title":"Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous antiinflammation and resolution.","volume":"73","author":"Serhan","year":"2005","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"R45-11-20210128","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0091-6749(89)90173-5","article-title":"Leukotrienes, LTC4 and LTB4, in bronchoalveolar lavage in bronchial asthma and other respiratory diseases.","volume":"84","author":"Wardlaw","year":"1989","journal-title":"J Allergy Clin Immunol"},{"key":"R46-11-20210128","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/1523-1747.ep12258678","article-title":"Leukotriene B4 induces in vitro fibroblast chemotaxis.","volume":"82","author":"Mensing","year":"1984","journal-title":"J Invest Dermatol"},{"key":"R47-11-20210128","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1183\/09031936.00143708","article-title":"Effects of a leukotriene B4 receptor antagonist on bleomycin-induced pulmonary fibrosis.","volume":"34","author":"Izumo","year":"2009","journal-title":"Eur Respir J"},{"key":"R48-11-20210128","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1164\/ajrccm.165.2.2104050","article-title":"Protection from pulmonary fibrosis in leukotriene-deficient mice.","volume":"165","author":"Peters-Golden","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"R49-11-20210128","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1093\/rheumatology\/keq271","article-title":"Increased cysteinyl-leukotrienes and 8-isoprostane in exhaled breath condensate from systemic sclerosis patients.","volume":"49","author":"Tufvesson","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"R50-11-20210128","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/art.11042","article-title":"Elevated levels of leukotriene B4 and leukotriene E4 in bronchoalveolar lavage fluid from patients with scleroderma lung disease.","volume":"48","author":"Kowal-Bielecka","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R51-11-20210128","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.prostaglandins.2008.12.003","article-title":"On the biosynthesis and biological role of eoxins and 15-lipoxygenase-1 in airway inflammation and Hodgkin lymphoma.","volume":"89","author":"Claesson","year":"2009","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"R52-11-20210128","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1136\/annrheumdis-2011-200745","article-title":"The 1215-lipoxygenase pathway counteracts fibroblast activation and experimental fibrosis.","volume":"71","author":"Kronke","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R53-11-20210128","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1002\/art.21432","article-title":"Cyclooxygenase- and lipoxygenase-derived eicosanoids in bronchoalveolar lavage fluid from patients with scleroderma lung disease: an imbalance between pro-inflammatory and anti-inflammatory lipid mediators.","volume":"52","author":"Kowal-Bielecka","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R54-11-20210128","first-page":"65","article-title":"Leukotriene inhibitors in the treatment of allergy and asthma.","volume":"75","author":"Scow","year":"2007","journal-title":"Am Fam Physician"},{"key":"R55-11-20210128","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/1465-9921-7-137","article-title":"Pharmacological inhibition of leukotrienes in an animal model of bleomycin-induced acute lung injury.","volume":"7","author":"Failla","year":"2006","journal-title":"Respir Res"},{"key":"R56-11-20210128","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1517\/14656566.2011.600689","article-title":"Montelukast for the treatment of asthma in the adult population.","volume":"12","author":"Amlani","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"R57-11-20210128","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ejphar.2010.09.084","article-title":"Effects of montelukast, a cysteinyl-leukotriene type 1 receptor antagonist, on the pathogenesis of bleomycin-induced pulmonary fibrosis in mice.","volume":"650","author":"Shimbori","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"R58-11-20210128","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/jat.1625","article-title":"Effect of leukotriene receptor antagonists on lung fibrosis in rats.","volume":"31","author":"Shaker","year":"2011","journal-title":"J Appl Toxicol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0b013e328356d9f6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T06:07:47Z","timestamp":1714198067000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201211000-00011"}},"subtitle":["emerging targets for therapy"],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0b013e328356d9f6","relation":{},"ISSN":["1040-8711"],"issn-type":[{"value":"1040-8711","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}